학술논문
Genome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis cases
Document Type
Report
Author
Source
The Pharmacogenomics Journal. August 1, 2014, Vol. 14 Issue 4, p356, 9 p.
Subject
Language
English
ISSN
1470-269X
Abstract
INTRODUCTION Juvenile idiopathic arthritis (JIA) is a heterogeneous condition with a variable outcome and considerable ongoing disease burden. (1) Studies indicate that functional disability and complications due to JIA are [...]
Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P The Pharmacogenomics Journal (2014) 14, 356-364; doi: 10.1038/tpj.2014.3; published online 8 April 2014 Keywords: juvenile idiopathic arthritis; methotrexate; pharmacogenetics; response
Clinical response to methotrexate (MTX) treatment for children with juvenile idiopathic arthritis (JIA) displays considerable heterogeneity. Currently, there are no reliable predictors to identify non-responders: earlier identification could lead to a targeted treatment. We genotyped 759 JIA cases from the UK, the Netherlands and Czech Republic. Clinical variables were measured at baseline and 6 months after start of the treatment. In Phase I analysis, samples were analysed for the association with MTX response using ordinal regression of ACR-pedi categories and linear regression of change in clinical variables, and identified 31 genetic regions (P The Pharmacogenomics Journal (2014) 14, 356-364; doi: 10.1038/tpj.2014.3; published online 8 April 2014 Keywords: juvenile idiopathic arthritis; methotrexate; pharmacogenetics; response